In a report released today, Jill Wu from CMB International Securities maintained a Buy rating on Thermo Fisher (TMO – Research Report), with a price target of $526.00.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Jill Wu’s rating is based on Thermo Fisher’s ability to navigate macroeconomic challenges effectively. Despite facing headwinds such as tariffs and changes in US domestic policies, the company managed to surpass revenue and adjusted EPS expectations in the first quarter of 2025. This performance is indicative of steady underlying demand across most of its business segments, particularly in the pharma and biotech markets.
Moreover, Thermo Fisher is taking strategic measures to counteract these macro challenges, including supply chain realignment and cost management. The company’s plans to invest $2 billion over the next four years in expanding its US manufacturing and R&D facilities further demonstrate its commitment to long-term growth. These factors, combined with the company’s competitive advantage in global manufacturing, contribute to Jill Wu’s Buy rating despite the revised forecasts and macro uncertainties.
In another report released yesterday, Bernstein also maintained a Buy rating on the stock with a $560.00 price target.
Based on the recent corporate insider activity of 93 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TMO in relation to earlier this year.